An experimental drug called RSO-021 controlled disease in 67% of patients at 12 weeks in a small phase 1 trial for relapsed pleural mesothelioma, according to a study published in Nature Communications. The...
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/fd5c53f8-5ed4-4621-868d-c4d4bdb6e378)